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Abstract: Objective: To delineate the phenotypic and genotypic spectrum in carriers of mitochondrial
MT-ATP6 mutations in a large international cohort. Methods: We analyzed in detail the clinical, genet-
ical, and neuroimaging data from 132 mutation carriers from national registries and local databases from
Europe, USA, Japan, and China. Results: We identified 113 clinically affected and 19 asymptomatic
individuals with a known pathogenic MT-ATP6 mutation. The most frequent mutations were m.8993 T
> G (53/132, 40%), m.8993 T > C (30/132, 23%), m.9176 T > C (30/132, 23%), and m.9185 T > C
(12/132, 9%). The degree of heteroplasmy was high both in affected (mean 95%, range 20%-100%) and
unaffected individuals (mean 73%, range 20%-100%). Age at onset ranged from prenatal to the age of
75 years, but almost half of the patients (49/103, 48%) became symptomatic before their first birthday.
In 28 deceased patients, the median age of death was 14 months. The most frequent symptoms were
ataxia (81%), cognitive dysfunction (49%), neuropathy (48%), seizures (37%), and retinopathy (14%). A
diagnosis of Leigh syndrome was made in 55% of patients, whereas the classic syndrome of neuropathy,
ataxia, and retinitis pigmentosa (NARP) was rare (8%). Conclusions: In this currently largest series of
patients with mitochondrial MT-ATP6 mutations, the phenotypic spectrum ranged from asymptomatic
to early onset multisystemic neurodegeneration. The degree of mutation heteroplasmy did not reliably
predict disease severity. Leigh syndrome was found in more than half of the patients, whereas classic
NARP syndrome was rare. Oligosymptomatic presentations were rather frequent in adult-onset patients,
indicating the need to include MT-ATP6 mutations in the differential diagnosis of both ataxias and
neuropathies.
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Felix Distelmaier, MD, Georg M. Stettner, MD, Boriana Büchner, MD, Marni J. Falk, MD, Johannes A. Mayr, PhD,
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To delineate the phenotypic and genotypic spectrum in carriers of mitochondrialMT-ATP6mutations in
a large international cohort.
Methods
We analyzed in detail the clinical, genetical, and neuroimaging data from 132 mutation carriers from
national registries and local databases from Europe, USA, Japan, and China.
Results
We identified 113 clinically affected and 19 asymptomatic individuals with a known pathogenicMT-ATP6
mutation. Themost frequent mutations were m.8993 T >G (53/132, 40%), m.8993 T >C (30/132, 23%),
m.9176 T >C (30/132, 23%), and m.9185 T >C (12/132, 9%). The degree of heteroplasmy was high both
in affected (mean 95%, range 20%–100%) and unaffected individuals (mean 73%, range 20%–100%). Age at
onset ranged from prenatal to the age of 75 years, but almost half of the patients (49/103, 48%) became
symptomatic before their first birthday. In 28 deceased patients, the median age of death was 14 months.
The most frequent symptoms were ataxia (81%), cognitive dysfunction (49%), neuropathy (48%), seizures
(37%), and retinopathy (14%). A diagnosis of Leigh syndrome was made in 55% of patients, whereas the
classic syndrome of neuropathy, ataxia, and retinitis pigmentosa (NARP) was rare (8%).
Conclusions
In this currently largest series of patients with mitochondrial MT-ATP6 mutations, the phenotypic
spectrum ranged from asymptomatic to early onset multisystemic neurodegeneration. The degree of
mutation heteroplasmy did not reliably predict disease severity. Leigh syndrome was found in more than
half of the patients, whereas classic NARP syndrome was rare. Oligosymptomatic presentations were
rather frequent in adult-onset patients, indicating the need to include MT-ATP6 mutations in the
differential diagnosis of both ataxias and neuropathies.
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The MT-ATP6 gene of the mitochondrial DNA (mtDNA)
(further named ATP6) encodes a subunit of the F1F0ATP-
synthase complex, a key enzyme of mitochondrial energy
metabolism.
Variants in ATP6 have long been recognized as a cause of
mitochondrial disease.1 Since the first description of a patho-
genic m.8993 T > G variant in 1992,1 more than 500 cases of
ATP6-associated disease have been reported.
The initially described phenotype is today referred to as the
syndrome of neuropathy, ataxia, and retinitis pigmentosa
(NARP). A more severe form of ATP6-associated disorders,
traditionally associated with high degrees of mutation
heteroplasmy,2,3 is maternally inherited Leigh syndrome
(LS), with early onset psychomotor developmental delay and
symmetrical lesions in basal ganglia and brainstem, often
leading to premature death.4 With the advent of next-
generation sequencing (NGS), less typical manifestations
have been observed, e.g., nonsyndromic sensorimotor neu-
ropathy;5 any combinations of ataxia, neuropathy, diabetes
mellitus, and hypergonadotropic hypogonadism;6 and mito-
chondrial myopathy, lactic acidosis, and sideroblastic anemia.7
Hence, the phenotypic spectrum of ATP6-associated mito-
chondrial disorders seems much broader than previously as-
sumed. So far, no systematic study on the clinicogenetic
spectrum of an extended cohort has been performed.
We report a cohort of 132 ATP6 mutation carriers from 11
countries, delineate phenotype and genotype, and evaluate
the role of heteroplasmy as a disease modifier.
Methods
Probands and design
This is a multicenter, retrospective, cross-sectional cohort
study. Probands with known pathogenic ATP6 variants were
identified from the registry of the German network for mi-
tochondrial disorders (mitoNET, n = 22) and 33 further di-
agnostic and research centers from Europe (n = 55), the USA
(n = 6), China (n = 37) and Japan (n = 18).
For data collection, patients’ physicians were asked to com-
plete a questionnaire which includes signs, symptoms, and
laboratory parameters. Detailed clinical histories of individual
patients are provided in table e-1, links.lww.com/NXG/A213.
Examinations and diagnostic procedures were performed and
evaluated by experienced medical professionals (neurologists,
pediatricians, child neurologists, pathologists, radiologists,
and clinical geneticists).
Review of the literature
A systematic review of the literature was conducted by
searching PubMed for all articles published from 1990 with
the terms “ATP6” and “ATPase6.”
Variants classified as confirmed disease-associated and
reported mutations in MITOMAP (mitomap.org) were in-
cluded in the analysis, for a total of 502. We reviewed the
reported variants for the range of heteroplasmy in affected
individuals and unaffected carriers, age at onset and pheno-
typic association (table e-2, links.lww.com/NXG/A214).
Molecular genetics
Individuals were screened for ATP6 mutations by using dif-
ferent approaches depending on the local facilities and year of
analysis, including targeted single-gene sequencing, high-
throughput panel sequencing, or whole-exome sequencing.
Levels of heteroplasmy in patients were assessed in leukocytes
(n = 114), skeletal muscle (n = 20), urine (n = 23), and
fibroblasts (n = 5).
Statistical analysis
Datasets were collected and organized in Microsoft Excel and
LibreOffice Calc and subjected to a basic descriptive analysis.
Deeper descriptive and explorative data analysis as well as
statistical testing was then performed in R (version 3.5.1) and
SPSS (version number 25). A group analysis of parametric
data was performed by one-way analysis of variance (ANOVA)
for comparison of means or byWelch test when Levene test for
homogeneity of variances failed. A post hoc group-wise analysis
was performed with Tukey Honestly Significant Difference
test. Although ANOVA is considered comparably robust to the
violation of the assumption of normality, we additionally per-
formed Kruskal-Wallis test with a post hoc group-wise analysis
with Wilcoxon rank sum test as a nonparametric alternative
when Shapiro-Wilk test for normal distribution of residues
failed. Analysis of nominal and ordinal data was performedwith
χ
2 test where applicable, and Fishers exact test was used where
the sample size did not permit for evaluation with χ2 test. The
significance level was corrected with the Bonferroni method for
multiple comparisons with p = 0.00094.
Standard protocol approvals, registrations,
and patients consents
All biological materials (tissue samples including blood, urine,
skin, muscle, and nerve and derivatives including DNA extracted
from tissues and cell lines), brain MRI scans, and medical and
neurophysiologic reports were obtained with written informed
consent of the probands, their parents, or legal guardians. The
local institutional review boards approved the study.
Glossary
LS = Leigh syndrome; mtDNA = mitochondrial DNA; NARP = neuropathy, ataxia, and retinitis pigmentosa; NGS = next-
generation sequencing; SARA = scale for assessment and rating of ataxia.
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Data availability
Anonymized data presented in this study will be made avail-
able on request by a qualified investigator. Requests should be
made to Thomas Klopstock.
Results
Our cohort of 132 mutation carriers consisted of 113 patients
and 19 asymptomatic relatives. Twenty-three cases have been
previously published.5,8–13 Because not every clinical feature
was assessed in every patient, we provide the number of
patients checked for a specific trait in the denominator and the
number of patients positive for this feature in the numerator.
Of all patients, 55% (62/112) had classic LS, 18% (20/112)
a Leigh-like phenotype, 8% (9/112) NARP syndrome, and
19% (21/112) other phenotypes, e.g., multisystemic ataxia,
polyneuropathy, or cardiomyopathy (table e-1, links.lww.
com/NXG/A213).
Mutational spectrum
We identified 8 previously reported pathogenic ATP6 variants
and 1 variant in the overlapping region of the ATP6 and ATP8
gene. Recurrent known pathogenic mutations found in our
cohort were m.8993 T >G (53/132 40%), m.8993 T >C (30/
132, 23%), m.9176 T > C (30/132, 23%), m.9185 T > C (12/
132, 9%), and m.9035 T > C (3/132, 2%). Single patients
(0.7%) carried the mutations m.8528 T > C, 8611_8612insC,
8969 G > A, and m.9134 A > G.
Degrees of heteroplasmy
In 105 patients and 19 asymptomatic mutation carriers, degrees
of heteroplasmy were determined in at least one of 5 tissues
(leukocytes, skeletal muscle, fibroblasts, urothelium, or buccal
swabs) (table e-1, links.lww.com/NXG/A213). In 21 probands,
more than 1 tissue was tested and there was a high correlation of
heteroplasmy degrees between tissues (table e-1). Degrees of
heteroplasmy ranged from 20% to 100% in patients with a me-
dian of 100% and average of 95% (figure 1A). In 88 of 105
affected individuals (84%), the mutation was detected with
a high degree of heteroplasmy (≥ 90% in at least one tissue), in
73 patients (70%) even homoplasmic. In the group of asymp-
tomatic carriers, heteroplasmy ranged from 20% to 100% with
a median of 77% and average of 73%. High degrees of hetero-
plasmy (≥90% in at least one tissue) were found in 37% (7/19)
of unaffected carriers, 4 being homoplasmic for a known path-
ogenic mutation (m.8993 T > C, n = 1; and m.9176 T > C, n =
3). Of note, 5 of 70 patients with LS (7%) showed a degree of
heteroplasmy below 90%. Patient 54-1 with a Leigh phenotype
harbored the variant m.8993 T > C even only at 67.8% heter-
oplasmy in leukocytes and 64.7% in urine cells (figure 1B).
Age at onset and time to diagnosis
Age at onset ranged from the prenatal period (e.g., micro-
cephaly or cardiomyopathy in fetal ultrasound imaging) to the
age of 75 years. Distribution by age categories is shown in figure
2A. Among the 4 most frequent genotypes in our cohort
(m.8993 T > G, m.8993 T > C, m.9176 T > C, and 9185 T >
C), the m.8993 T >Gmutation had a significantly earlier onset
than the other genotypes (p = 0.0003) (figure 2B).
At the time of writing, 28% (28/99) of the patients were
deceased with a median age of death of 12 months (range: 5
months to 68 years, mean 4.7 years). All deceased patients had
become symptomatic during infancy or childhood, and more
than half of them died within the first 2 years of life (57%, 16/
28). All except one suffered from Leigh or Leigh-like syn-
drome (96%, 27/28), and half of them harbored them.8993 T
> G mutation (14/28).
We investigated the lag time between onset of symptoms and
molecular diagnosis in 3 subgroups: (1) age at onset in infancy
(47/ 101), (2) in early childhood (age 1–6; 28/ 101), and (3)
above the age of 6 years (26/ 101). The mean delay in di-
agnosis was 1.79 years (range 0–19; SD 3.31; median: 0.58)
in group 1, 5.39 years (range: 0–30; SD 8.33; median: 1) in
group 2, and 12.2 years (range: 0–60; SD 14.6; median: 7) in
group 3, implying a correlation of time to diagnosis with the
age at onset (p = 0.00085). This was further specified when
comparing subgroups individually, with statistical significance
reached for comparison of groups 1 and 3 (p = 0.00019), and
a tendency showing when comparing groups 2 and 3 (p =
0.038), indicating that later onset of symptoms may lead to
a longer delay until molecular diagnosis (figure 2C).
Phenotypic spectrum
Clinical findings in our cohort are summarized in figure 3 and
table e-1, links.lww.com/NXG/A213.
LS was the most frequent phenotype (62/112; 55%). In this
subgroup, nearly half of the patients (30/62; 48%) harbored
the m.8993 T > G variant, followed by m.9176 T > C (14/62;
23%), m.8993 T > C (12/62; 19%), and m.9185 T > C (5/62;
8%) and 1 patient with the rare variant m.8969 G > A. Most of
the patients with LS became symptomatic in infancy and early
childhood (55/ 60; 92%); oldest age at onset was 16 years
(patient 29-1). In addition, 20 children showed clinical symp-
toms compatible with the diagnosis of LS, but brain MRI was
either not available (11/ 20; 55%) or MRI findings were dis-
tinct from classic LS, showing no basal ganglia or brainstem
lesions but delayedmyelination (3/20; 15%), cerebral atrophy/
microcephaly (3/20; 15%), or no pathology at all (3/20; 15%).
Only 9 patients in our cohort exhibited a NARP phenotype
(8%), 6 of those with additional signs (e.g., cognitive dys-
function, global developmental delay, and seizures). In 6/9
patients (67%), the degree of heteroplasmy was 100%, whereas
it was lower in the other 3 (90%, 80%, and 59%, respectively).
Most patients evaluated for cerebellar symptoms showed
cerebellar ataxia (68/84; 81%), 26% of those in combination
with a sensory ataxia (18/68; 26%). One patient showed signs
of sensory ataxia without having additional cerebellar signs.
Symptoms in 16% of adult patients (18/112) were rated using
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a scale for assessment and rating of ataxia (SARA). The me-
dian score was 8.5/40 (mean 10/40, range 1–40/40).
Peripheral neuropathy was suspected in 36 of 40 (90%)
patients assessed for clinical symptoms and signs of peripheral
nerve dysfunction; in 19 patients (19/40, 48%), nerve con-
duction studies and EMG confirmed the diagnosis. One patient
without clinically apparent neuropathy showed neurophysio-
logic findings of a peripheral neuropathy. Neuropathy was
predominantly axonal and sensory in 10 patients, whereas in
the other 9 patients, detailed electrophysiologic data were not
available.
Any form of cognitive dysfunction was reported in 49% (43/
87) of the patients, ranging from mild learning disabilities to
severe mental retardation or secondary cognitive decline.
Epileptic seizures were reported in 37% (35/95) of patients,
mostly in Leigh or Leigh-like syndrome (30/35, 86%) but also
in NARP syndrome (4/9, 44%).
Overall, 14 of 70 patients (20%) with an ophthalmologic as-
sessment showed (nonmuscular and noncerebellar) ocular
symptoms. Ten patients (10/70, 14%) had a retinopathy,
mostly (9/10, 90%) in the context of NARP syndrome. Other
ocular symptoms included optic atrophy in 4/70 (6%) and
cataract in 3/70 (4%) patients.
Cardiac symptoms were reported in 11/80 patients (14%).
Three had cardiac arrhythmia, which manifested as Wolff-
Parkinson-White syndrome in 2 (carrying the mutations
m.9185 T > C and m.8993 T > C). Six patients had
cardiomyopathy.
Figure 1 Distribution of the degrees of heteroplasmy
(A) Distribution of the degrees of heteroplasmy in differentMT-ATP6-associated phenotypes and asymptomatic carriers. 1 = Leigh/Leigh-like syndrome; 2
= NARP syndrome; 3 = other phenotypes; 4 = asymptomatic carrier. (B) Heteroplasmy grades in every single patients. Each circle represents an individual
with aMT-ATP6mutation. The different tissues used for heteroplasmy assessment are represented by different colors. In probands, wheremore than one
tissue was evaluated for heteroplasmy (n = 21), the highest value was selected. All values in all available tissues are shown in table e-1, links.lww.com/
NXG/A213. 1 = Leigh/Leigh-like syndrome; 2 = NARP syndrome; 3 = other phenotypes; 4 = asymptomatic carrier. NARP = neuropathy, ataxia and retinitis
pigmentosa.
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One patient (85-1) carrying the m.9176 T > C variant had
a chronic progressive external ophthalmoplegia as a first sign,
which is unusual in reported ATP6 patients.
We examined correlation of distinct genotypes with the oc-
currence of specific phenotypes or symptoms. A Leigh/Leigh-
like syndrome (43/47; 91%) was more common in patients
harboring the m.8993 T > G variant (22/39; 56%) than in
patients carrying other variants. No other pathogenic variant
appeared to be predictive of distinct symptoms or signs (table
1). There was, however, a tendency toward a higher pro-
portion of seizures in patients with the m.8993 T > G variant
(22/39 patients, 56%) as compared with patients with other
variants (12/51 patients, 24%) (p = 0.0021) and a trend
toward lower proportion of cognitive dysfunction in patients
with the m.9176 T > C variant (4/21 patients, 19%) as
compared with patients with other variants (34/59 patients,
58%) (p = 0.0044).
Twelve of our patients manifested in adulthood were mono-
symptomatic or oligosymptomatic and had a relatively mild
disease course. One patient showed isolated sensorimotor
neuropathy (patient 2-3) and another had pure cerebellar
ataxia (patient 96-1). Six patients exhibited signs of neurop-
athy plus cerebellar ataxia, spasticity, or cognitive dysfunction.
Two adult patients presented with a NARP phenotype
(patients 25-1 and 28-1).
Neuroimaging data
Brain MRI findings in ATP6 patients are presented in figure
4, A–F. Brain MRI data were available for 85 patients, which
showed abnormalities in 81 (95%) patients. Basal ganglia
and brain stem lesions, usually found in classic LS, were
reported in 65% (55/85) and 32% (27/85) of the patients,
respectively, with 22% (19/85) patients showing both
alterations. Cerebellar atrophy was present in 16% (14/85),
and cortical/subcortical atrophy was identified in 13% (11/
85). Other less frequent signs were white matter lesions in 5
patients, delayed myelination in 4 patients, and microceph-
aly in 2 patients. Brain MRI was reported normal in 4
patients.
In 20 cases, muscle biopsy specimens were studied histolog-
ically, and evaluation was either normal (9/20 cases) or dis-
closed unspecific changes (11/20 cases). Ragged red fibers
were found only in 1 adult patient carrying a m.9035 T > C
mutation who presented with ataxia in his late 50s and dis-
played no clinical signs of myopathy.
Discussion
Our study presenting the currently largest series of patients with
mitochondrial disease has 2 major results: First, it broadens the
clinical spectrum of ATP6-associated mitochondrial disorders
Figure 2 Distribution of age at onset and time diagnosis
(A) Age at symptom onset (years). (B) Distribution of age at symptom onset
grouped bymutation. (C) Lag time between age at symptomonset and age at
molecular diagnosis in 3 different age groups in years (0–1 1–6, >6).
Figure 3 Distribution and frequency of phenotypes and
symptoms in our cohort
Bars indicate the percentage of patients with a given phenotype (green bars)
or symptom (blue bars) of the total assessed for this phenotype or symptom.
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and shows that the clinical spectrum is more heterogeneous
than previously reported. Second, it shows that the degree of
mutation heteroplasmy does not strictly correlate with disease
severity, with homoplasmic mutations found not only in LS but
also in milder cases and even asymptomatic probands.
The phenotypic spectrum in our cohort ranged from asymp-
tomatic mutation carriers to fatal, early onset, and multi-
systemic neurodegenerative disease with severe disability.Most
affected children presented with an overall homogeneous Leigh
or Leigh-like syndrome phenotype (73%; 82/112) with de-
velopmental delay and hypotonia as first signs.One exception is
patient 29-1 who showed first symptoms at the age of 16 years
with acute brainstem dysfunction with dysarthria, dysphagia,
tetraparesis, and ophthalmoplegia, followed by respiratory in-
sufficiency and coma. Brain MRI revealed extensive lesions in
the basal ganglia, brainstem, and cerebellum. Patient 85-1 showed
isolated chronic progressive external ophthalmoplegia at the age
of 10 years, followed by respiratory and cardiac failure. BrainMRI
revealed Leigh-like abnormalities in the dorsal midbrain and
hypothalamus. About half of the deceased patients in our cohort,
mostly severely affected children, carried the mutation m.8993
T > G. Together with the higher proportion of seizures in the
m.8993 T >G group, this implies that the m.8993 T >G variant
might be associated with a more severe course of disease.14
Only 9 patients in our cohort (8%) presented with a NARP
phenotype, and 6 of those showed severe additional signs and
symptoms such as epilepsy, cognitive dysfunction, delayed
myelination, and Leigh-like changes. This low frequency of
the NARP phenotype was unexpected because NARP has
been regarded as a frequent ATP6-associated disorder.15 All 6
of our patients with NARP with additional features (patient 4-
1, 5-1, 5-2, 8-1, 28-1, and 43-1) showed some overlap to
a Leigh-syndrome phenotype as they exhibited a global de-
velopmental delay, mental retardation, and/or seizures.
Patients 8-1 and 28-1 displayed, besides a severe cognitive
impairment (mental retardation), Leigh-like alterations in
brain MRI scans.
On the mild end of the spectrum, 13% (15/112) of our
patients exhibited a monosymptomatic or oligosymptomatic
disease (mainly cerebellar ataxia and neuropathy), including
all patients with adult onset (12/103). Early manifestation
(<1 year) was observed in almost half of the patients (48%,
49/103). However, adult onset was observed in 12% (12/
103), stressing that ATP6-associated mitochondrial disorder
is not restricted to infancy or childhood-onset. Early onset was
observed mostly in patients with a severe course of disease
(Leigh or Leigh-like syndrome). Later onset showed a signif-
icant correlation with a larger delay until the molecular di-
agnosis was established. One obvious explanation for this
finding is that there is a clear need for a fast and broad di-
agnostic workup if the disease starts early in life and takes
a life-threatening course such as in children with LS, whereas
staged diagnostic approaches for milder presentations such as
neuropathy and ataxia rarely include ATP6 diagnostics. To
avoid this unnecessary delay in diagnosis, ATP6-associated
mitochondrial disorders should be considered in mono-
symptomatic or oligosymptomatic presentations that have
not previously been considered typical for ATP6-associated
disease, such as isolated neuropathy or ataxia. The ATP6 gene
should be included in routine NGS panel diagnostics for the
differential diagnosis of both ataxias and neuropathies and
comprehensive genetic testing via whole-exome sequencing
should cover mtDNA in addition to nuclear DNA in a clinical
diagnostic setting.16
Clinical variability between patients with the same genotype
was high in our cohort, not only interfamilial but also intra-
familial. Of note, the monozygotic twin sisters 3-1 and 3-2,
both harboring the homoplasmic m.8993 T > C mutation
show very different disease courses. Patient 3-1 showed a se-
vere gait ataxia because of a combination of sensorimotor
polyneuropathy and cerebellar ataxia starting at age 2 years
and has been has been using a wheelchair from the age of 16
years (SARA score 18.5/40), whereas her sister was only
slightly affected with mild gait ataxia from the age 7 of years.
She was able to walk unaided at age 16 (SARA score 3/40).
Table 1 Comparison of the frequency of phenotypes and symptoms among carriers of different MT-ATP6 mutations
Variant
Leigh/Leigh-







m.8993T > G vs m.8993T > C,
m.9176T > C, m.9185T > C
0.0005a 0.4274a 0.7711a 0.022a 0.0019a 0.0021a 1.0b 0.4732b
m.8993T > C vs m.8993T > G,
m.9176T > C, m.9185T > C
0.1126a 0.3492a 0.3329b 0.7931a 0.2742b 0.8011a 0.4375b 0.6771b
m.9176T > C vs m.8993T > G,
m.8993T > C, m.9185T > C
0.1126a 0.8146a 0.1025a 0.0044a 0.6618b 0.0191a 0.1868a 0.6771b
m.9185T > C vs m.8993T > G,
m.8993T > C, m.9176T > C
0.2593b 0.7370b 0.19212 1.0b 0.0473b 0.3084b 0.6255b 0.2878b
Abbreviation: LS = Leigh syndrome.
p values of χ2 Pearson or Fishers exact are shown. Significance level was defined as p < 0.0009 after Bonferroni correction for multiple testing.
a Chi square Pearson (2-sided p values).
b Fishers Exact (2-sided p values).
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A generally accepted preconception about mitochondrial
disease because of mtDNA variants is a direct correlation of
symptom severity to degree of heteroplasmy. It is widely
believed that a percentage of heteroplasmy >90% for the
m.8993 T > C/G variant leads to LS, whereas a heteroplasmy
load between 70% and 90% results in a NARP
phenotype.17,18 This idea has recently been challenged.19
Our findings of a high grade of heteroplasmy in the
asymptomatic carrier group (7/17 ≥ 90%, 4/17 homo-
plasmic for known pathogenic mutations) and the observa-
tion of moderate degrees of heteroplasmy in several early
onset symptomatic patients support the view that hetero-
plasmy load alone is insufficient to explain disease severity.
For instance, patient 54-1 presenting with a LS showed onset
in infancy and harbored the m.8993 T > C variant at mod-
erate degrees of heteroplasmy (68% in leukocytes and 65%
in urine cells). By contrast, the asymptomatic mother
(proband 59-2) of a patient with LS harbored the same
variant even at higher degrees of heteroplasmy (78% leu-
kocytes and 88% urine cells). In 3 asymptomatic carriers
harboring the m.8993 T > G (proband 49-1) and the m.9176
T > C (proband 69-3, 69-4) variants, the high degrees of
heteroplasmy have to be interpreted with caution because
they are children and might still develop symptoms later in
life.
Degrees of heteroplasmy in our multicentric study were
determined in different tissues, at different ages, and with
different methods, warranting careful interpretation. How-
ever, age differences in measurements of heteroplasmy may
have a negligible impact at least for the m.8993 variant be-
cause it has been shown that heteroplasmy of m.8993 T > G/
C does not change significantly over time.20 Moreover, we
found a very high correlation of degrees of heteroplasmy
between different tissues in 21 probands (table e-1, links.
lww.com/NXG/A213).
Further modifying factors determining disease manifestation
may include the mtDNA background, which has been shown
to play an important role in modulating the biochemical
defects and clinical outcome.21 For example, the variants
m.8741 T > G and m.8795 A > G have been reported to be
Figure 4 Examples of brain MRI changes detected in patients with MT-ATP6-associated disease
Number of the patient is given in the middle of the images. (A) FLAIR sequence of axial view showing symmetrical bilateral hyperintensities and
partly cystic degeneration in the caudate nuclei and putamen (arrows on the left image), as well as bilateral hyperintensities in the medulla
oblongata and hyperintensities on the left cerebellar hemisphere (arrows on the right image). (B) Sagittal view of T1 sequence shows a pronounced
fronto-parietal and cerebellar atrophy. (C) Axial view of T2 sequence shows subtle unilateral hyperintensities in the left putamen (arrow on left and
right image). (D) T2 sequence of sagittal view reveals a microcephaly and hypoplasia of the brainstem and cerebellum. (E) axial view of FLAIR
sequence shows bilateral putaminal and caudate head signal alterations, atrophy and cystic changes (arrows on left image). Axial view of T2
sequence reveals a slight cerebellar atrophy and bilateral T2 hyperintensities within the cerebellar peduncles (right image). (F) T1 sequence of
sagittal view shows cerebellar and cerebral atrophy and thinning of the corpus callosum (arrows on the left image), whereas basal ganglia structure
appeared normal (arrows on right side). FLAIR = fluid-attenuated inversion recovery.
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protective factors for the m.8993 T > G mutation causing
a LS.22 mtDNA copy number may be another modifying
factor of disease severity because it has recently been shown
for the m.3243 A > Gmutation,23 but so far, there are no data
on this in ATP6-associated disorders. Furthermore,
ATP6 variants may not be fully penetrant, even when
homoplasmic.8
In essence, our study demonstrates that ATP6 variants cause
a continuous disease spectrum rather than a group of distinct
clinical syndromes. Early onset was associatedwith amore severe
course of disease, especially in patients carrying the m.8993 T >
G variant. Onset after the age of 6 years leads to a considerable
delay in diagnosis, most likely because of monosymptomatic and
oligosymptomatic presentations, especially in the adult group.
Including ATP6 mutation screening in routine diagnostics for
neuropathy and ataxia will benefit patients regarding a prompter
and correct diagnosis and genetic counseling.
Our observations strongly support the notion that the degree
of heteroplasmy alone cannot reliably predict disease severity.
Further studies are needed to identify factors that modulate
prognosis.
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